AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G] Tarsus Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:07/28/2025
Deep Track Biotechnology Master Fund, Ltd.
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:07/28/2025
David Kroin
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:07/28/2025
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of July 28, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person The amount beneficially owned by each Reporting Person is determined based on 42,014,237 Common Stock outstanding as of April 24, 2025, according to the issuer's 10-Q filed with the SEC on May 1, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: July 28, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

TARS Rankings

TARS Latest News

TARS Latest SEC Filings

TARS Stock Data

2.39B
39.21M
3.24%
117.72%
19.28%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
IRVINE